T-vec | search
Click here to view T-vec news from 60+ newspapers.
Bookmark or Share- IMLYGIC® (talimogene laherparepvec) | Patient InformationIMLYGIC® (talimogene laherparepvec) is a prescription medication used to treat a type of skin cancer called melanoma when it is on your skin or in your lymph glands. IMLYGIC® may not help you live longer and may not shrink cancer in your organs (for example, lung or liver).
- Talimogene Laherparepvec - NCI - National Cancer InstituteYes. FDA label information for this drug is available at DailyMed. Use in Cancer. Talimogene laherparepvec is approved to treat: Melanoma in the skin and lymph nodes that cannot be removed by surgery. It is used as local treatment in patients whose disease has come back after being treated with surgery.
- Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy ...Talimogene laherperepvec (T-VEC) is an injectable modified oncolytic herpes virus being developed for intratumoral injection, that produces granulocyte-macrophage colony-stimulating factor (GM-CSF) and enhances local and systemic antitumor immune responses.
- FDA Approves T-VEC to Treat Metastatic Melanoma - NCIOn October 27, the U.S. Food and Drug Administration (FDA) approved the first oncolytic virus therapy, talimogene laherparepvec (T-VEC, or Imlygic®).The agency approved T-VEC for the treatment of some patients with metastatic melanoma that cannot be surgically removed.
- Review of talimogene laherparepvec: A first-in-class oncolytic viral ...Talimogene laherparepvec (T-VEC) is an oncolytic virus based on herpes simplex virus type 1 approved for intralesional treatment of advanced melanoma. In this article, we review the clinical literature on T-VEC for advanced melanoma and provide a practical approach to using T-VEC in the dermatologic surgery and oncology clinic.
More
